New Technology and Workflow for Integrated Collection, Stabilization, and Purification of Circulating Cell-Free DNA
1 Sept 2016
Watch this video to find out how PreAnalytiX have developed the PAXgene® Blood ccfDNA System, to meet the increase in Research into non-invasive prenatal testing (NIPT) and circulating tumor DNA (ctDNA) testing based on circulating cell-free DNA (ccfDNA). PAXgene® Blood ccfDNA works to preserve the extracellular levels of ccfDNA. This presentation presents results of ccfDNA testing of the new system compared to whole blood samples collected in the BD Vacutainer® K2EDTA Tube and the Streck CellFree DNA BCT®.
About the company
QIAGEN
QIAGEN is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA, and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analysis.
We have developed and market more than 500 consumable products and automated solutions. The company provides these products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics.
QIAGEN employs more than 3,600 people in over 35 locations worldwide.
